Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-23T04:34:23.201Z Has data issue: false hasContentIssue false

Paliperidone LAI-Induced Leukocytopenia: A Case Report

Published online by Cambridge University Press:  27 August 2024

K. Laškarin*
Affiliation:
1University Psychiatric Hospital “Sveti Ivan”, Zagreb
K. Matić
Affiliation:
1University Psychiatric Hospital “Sveti Ivan”, Zagreb 2Faculty of Dental Medicine and Health “Josip Juraj Strossmayer” University of Osijek, Osijek
S. Vuk Pisk
Affiliation:
1University Psychiatric Hospital “Sveti Ivan”, Zagreb 2Faculty of Dental Medicine and Health “Josip Juraj Strossmayer” University of Osijek, Osijek
M. Grah
Affiliation:
1University Psychiatric Hospital “Sveti Ivan”, Zagreb 2Faculty of Dental Medicine and Health “Josip Juraj Strossmayer” University of Osijek, Osijek
V. Grošić
Affiliation:
1University Psychiatric Hospital “Sveti Ivan”, Zagreb 2Faculty of Dental Medicine and Health “Josip Juraj Strossmayer” University of Osijek, Osijek
I. Filipčić
Affiliation:
1University Psychiatric Hospital “Sveti Ivan”, Zagreb 2Faculty of Dental Medicine and Health “Josip Juraj Strossmayer” University of Osijek, Osijek 3School of Medicine, University of Zagreb, Zagreb, Croatia
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Antipsychotics effectively manage psychotic symptoms but may have side effects. Patients with schizophrenia often lack insight into their condition, leading to nonadherence. Long-acting injectable (LAI) antipsychotics aim to overcome this, reducing relapse risks. Paliperidone LAI, a second-generation antipsychotic, has a lower side effect profile when compared to first-generation counterparts. Blood dyscrasias, like neutropenia and lymphopenia, increase infection susceptibility. This case report describes an instance of leukocytopenia arising during paliperidone LAI treatment, which quickly resolved after the discontinuation of the medication.

Objectives

This case report describes an instance of leukocytopenia arising during paliperidone LAI treatment, which quickly resolved after the discontinuation of the medication.

Methods
Results

CASE

A 42-year-old female with schizophrenia, nonadherent to previously prescribed medication was admitted to our acute psychiatric department. She experienced positive symptoms (paranoid delusions), as well as disorganized thinking and behavior. Oral risperidone 4 mg two times a day was recommenced and titrated with mild improvement in her psychotic symptoms with the idea of switching to paliperidone LAI and eventually ceasing oral medication. Oral paliperidone was unavailable for prescription due to local restrictions. At admission her routine laboratory tests showed no abnormalities, but 5 days after receiving paliperidone LAI, routine laboratory tests showed a strong decrease in her WBC and absolute neutrophilic and lymphocytic count ( Lkc 2.89x109/L, Neut 1.57x 109/L, Lym 0.88x 109 /L ). Antipsychotic-induced blood dyscrasia was suspected and paliperidone depot was discontinued. The patient had rapid improvement in her WBC reaching the reference range in 10 days ( Lkc 4.23 x 109/L, Neut 2.51x10 9/L, Lym 0.98x 109/L). Sertindole was introduced consdering her history of a good therapeutic response to the drug, with improvement in psychotic symptoms. She is currently stable taking sertindole 16 mg/day, clonazepam 2 mg/day and alprazolam 0.5 mg/day.

DISCUSSION

The onset of neutropenia and lymphopenia post-paliperidone LAI initiation, resolving in 10 days,, indicate a direct association. Few cases report to date describe paliperidone-induced leukocytopenia, with rapid recovery post-discontinuation. Proposed mechanisms include bone marrow suppression and peripheral WBC destruction. It has been proposed that drug-induced neutropenia is often dose-dependent, which could explain why our patient exhibited tolerability to risperidone but developed cytopenia upon transitioning to depot paliperidone.

Conclusions

While cases of agranulocytosis have been reported in association with the use of other antipsychotics these antipsychotics do not require the same monitoring as clozapine. Our case emphasizes the need for vigilant blood dyscrasia monitoring during antipsychotic therapy.

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.